Comparative in vitro activity of aztreonam-avibactam and aztreonam plus ceftazidime-avibactam against Stenotrophomonas maltophilia complex
{{output}}
Members of the Stenotrophomonas maltophilia complex are intrinsically multidrug-resistant pathogens that disproportionately affect critically ill patients. Aztreonam-avibactam (ATM-AVI), FDA approved in 2025, combines aztreonam (ATM; stable to L1 β-lactamase)... ...
